BioTime’s CEO Michael West Presents 12 New ACTCellerateTM Cell Lines And New PureStemTM Products Slated For Launch In 2011 At GTCbio Stem Cell Conference Today
BioTime, Inc. (NYSE Amex:BTIM) announced that the Company’s CEO Dr. Michael West will present data today relating to 12 new cell lines, differentiation kits, and cell culture media at the GTCbio 4th Advances in Stem Cell Discovery and Development Conference in San Francisco, California. Dr. West’s presentation titled: “Fate Space Screening of Clonal Human ES-derived Embryonic Progenitor Cell Lines” will include a discussion of the Company’s proprietary bank of more than 140 diverse human cell types made from human embryonic stem cells, the company’s screening technology for discovering means of manufacturing human cell types, and the potential use of these cells for diverse new therapeutics and drug discovery.
During his lecture, Dr. West will describe the 12 new lines: B28, EN23, Z3, EN5, RASMO19, EN27, T42, SK47, SM2, SK46, T44, and SK44 that will be launched beginning November 1, 2010. He also will disclose new data on the cell lines: SK17 that have the potential to differentiate into cells that express renin and smooth muscle cell-related genes characteristic of the juxtaglomerular apparatus of the kidney, Z2 that when differentiated using a proprietary protocol expresses relatively high levels of the bone growth factor genes BMP2 and BMP7 (also known as osteogenic protein-1 (OP-1), and J16 that expresses preadipocyte markers of interest to researchers in cosmetic dermatology and type II diabetes.
In addition, Dr. West will disclose for the first time the Company’s PureStem TM technology, with which the Company plans to expand its product offerings in calendar year 2011. The PureStem TM technology utilizes the expression of exogenous transcriptional regulators to control the differentiation of human embryonic stem cells and induced plutipotent stem cells, and may potentially provide many new human cell types needed in regenerative medicine. BioTime is seeking patent protection for the PureStem TM technology.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV